| Literature DB >> 28167964 |
A Anagnostopoulos1, S Mitra2, B Decruze1, R Macdonald1, J Kirwan1.
Abstract
Objective. To compare the safety, efficacy, and direct cost during the introduction of laparoscopic radical hysterectomy within an enhanced recovery pathway. Methods. A 1 : 1 single centre retrospective case control study of 36 propensity matched pairs of patients receiving open or laparoscopic surgery for early cervical cancer. Results. There were no significant differences in the baseline characteristics of the two cohorts. Open surgery cohort had significantly higher intraoperative blood loss (189 versus 934 mL) and longer postoperative hospital stay (2.3 versus 4.1 days). Although no significant difference in the intraoperative or postoperative complications was found more urinary tract injuries were recorded in the laparoscopic cohort. Laparoscopic surgery had significantly longer duration (206 versus 159 minutes), lower lymph node harvest (12.6 versus 16.9), and slower bladder function recovery. The median direct hospital cost was £4850 for laparoscopic radical hysterectomy and £4400 for open surgery. Conclusions. Laparoscopic radical hysterectomy can be safely introduced in an enhanced recovery environment without significant increase in perioperative morbidity. The 10% higher direct hospital cost is not statistically significant and is expected to even out when indirect costs are included.Entities:
Year: 2017 PMID: 28167964 PMCID: PMC5259609 DOI: 10.1155/2017/2103763
Source DB: PubMed Journal: Obstet Gynecol Int ISSN: 1687-9597
Clinical and pathological baseline patient characteristics.
| LRH ( | ARH ( |
| |
|---|---|---|---|
| Age mean | 44.6 | 41.2 | 0.2 |
| Range (SD) | 24–79 (12.2) | 24–73 (12.7) | |
| BMI mean | 25.8 | 26.4 | 0.5 |
| Range (SD) | 19.6–35.8 (3.8) | 19.5–34.7 (4.7) | |
| ASA grade | 0.06 | ||
| 1 | 26 (72%) | 18 (50%) | |
| ≥2 | 10 (28%) | 18 (50%) | |
| FIGO stage | 0.2 | ||
| IA2 | 1 (2.7%) | 0 | |
| IB1 | 33 (91.8%) | 36 (100%) | |
| IIA1 | 2 (5.5%) | 0 | |
| Histology | 0.3 | ||
| Squamous cell | 25 (69%) | 20 (55%) | |
| Adenocarcinoma | 11 (31%) | 16 (45%) | |
| Grade | 0.3 | ||
| 1 | 5 (13.8%) | 12 (33.3%) | |
| 2 | 16 (44.4%) | 15 (41.6%) | |
| 3 | 3 (8.5%) | 3 (8.5%) | |
| n/a | 12 (33.3) | 6 (16.6%) | |
| Tumor max dimension | 0.6 | ||
| Median | 19.5 mm | 16 mm | |
| Range (IQ) | 7–37 (30) | 9–35 (12) | |
| Nodal metastasis | 4 (11%) | 2 (5.5%) | 0.3 |
| Previous minor abdominal surgery | 7 (19.4%) | 13 (26%) | 0.1 |
| Follow-up duration (months) | 36 | 36 | 1 |
These patients were preoperatively staged as IB1.
Surgical safety outcomes.
| LRH | ARH |
| |
|---|---|---|---|
|
| 6 (16.6%) | 8 (22.2%) | 0.5 |
| Bladder | 2 (5.5%) | 0 | 0.1 |
| Ureteric | 1 (2.7%) | 1 (2.7%) | 1 |
| Bowel | 1 (2.7%) | 0 | 0.3 |
| Vascular | 1 (2.7%) | 2 (5.5%) | 0.5 |
| Nerve permanent | 1 (2.7%) | 2 (5.5%) | 0.5 |
| Haemorrhage > 1.5 lt | 0 | 3 (8.3%) | 0.07 |
|
| 3 (11.1%) | 4 (11.1%) | 0.6 |
| Surgical site complications | |||
| Wound/vault dehiscence | 2 (5.5%) | 3 (11.1%) | 0.5 |
| Infection | 1 (2.7%) | 3 (8.3%) | 0.3 |
| VTE | 1 (2.7%) | 0 | 0.3 |
|
| |||
| Admissions to HDU | 0 | 2 (5.5%) | 0.1 |
| Blood transfusion | 1 (2.7%) | 11 (30.5%) | <0.05 |
|
| |||
| A&E reviews | 10 (27.7%) | 8 (22.2%) | 0.5 |
| Readmissions | 8 (22.2%) | 5 (13.8%) | 0.3 |
| Reoperations (minor) | 2 (5.5%) | 5 (13.8%) | 0.2 |
| Reoperations (major) | 3 (8.3%) | 1 (2.7%) | 0.3 |
VTE: venous thromboembolism, HDU: high dependency unit, and A&E: accidents and emergency.
Overall complication grade.
| Grade | LRH ( | ARH ( |
|
|---|---|---|---|
| I | 2 (5.5%) | 2 (5.5%) | 1 |
| Id | 2 (5.5%) | 2 (5.5%) | 1 |
| II | 6 (16.6%) | 8 (22.2%) | 0.5 |
| IIIb | 5 (13.8%) | 5 (13.8%) | 1 |
| IVa | 0 | 1 (2.7%) | 0.3 |
d: long-term disability.
Surgical efficacy outcomes.
| LRH | ARH |
| |
|---|---|---|---|
| Involved excision margins | 1 (2.8) | 1 (2.8%) | 1 |
| Closest excision margin mean in mm | 6.8 | 6.3 | 0.7 |
| Range (SD) | 0.5–14 (4.3) | 0.5–20 (5) | |
| Pelvic lymph node harvest mean (SD) | 12.6 (5.3) | 16.9 (8) | <0.05 |
| Vaginal vault length mean in mm (SD) | 16.7 (9.4) | 14.7 (9.8) | 0.3 |
| Operation time in minutes mean (SD) | 206 (37.7) | 159 (48.4) | <0.05 |
| Range | 101–268 | 75–359 | |
| Days of hospital stay mean (SD) | 2.31 (0.71) | 4.17 (1.34) | <0.05 |
| Range | 1–4 | 2–8 | |
| Bladder function recovery | |||
| TWOC > 1 | 13 (36.2%) | 4 (11.1%) | <0.05 |
| Urogynaecology review | 4 (11.1%) | 4 (11.1%) | 1 |
| ISC | 1 (2.7%) | 1 (2.7%) | 1 |
| Bowel function recovery | |||
| Constipation | 3 (8.3%) | 1 (2.7%) | 0.3 |
| Adjuvant treatment | 5 (13.8%) | 1 (2.7%) | 0.08 |
| Recurrence | 0 | 0 | 1 |
TWOC: trial without catheter and ISC: intermittent self-catheterisation.
Early postoperative PROM.
| LRH | ARH |
| |
|---|---|---|---|
|
| |||
| Stairs | 100% | 91.3% | 0.1 |
| Out of house | 62.5% | 63% | 0.9 |
|
| |||
| Use of analgesia | 63.9% | 55.6% | 0.7 |
| Effective analgesia | 72.2% | 58.3% | 0.4 |
|
| |||
| Eating & drinking | 61.1% | 52.8% | 0.7 |
| Nausea & vomiting | 5.6% | 11.1% | 0.4 |
| Bowels open | 47.2% | 63.9% | <0.05 |
| Use of laxatives | 69.4% | 38.9% | <0.05 |
|
| 0 | 8.3% | 0.1 |
PROM: patient reported outcome and GI: gastrointestinal.
Direct hospital cost.
| Cost of | LRH | ARH |
|
|---|---|---|---|
| Standard surgical consumables | 715.89 | 160.12 | |
| Extra perioperative expenses median (IQR) | 412.2 (300) | 307.5 (371) | 0.9 |
| Surgical time mean (SD) | 3571.8 (651) | 2759 (836) | <0.05 |
| Length of hospital stay median (IQR) | 600 (300) | 1200 (600) | <0.05 |
| Total median (IQR) | 4746.9 (948) | 4580.9 (1433) | 0.08 |